Israeli Biopharmaceutical Company ready to produce the experimental Ebola vaccine, ZMapp

An Israeli Biopharmaceutical company has said it has the resources to produce the experimental Ebola vaccine, ZMapp, which has recently run out.

The executive vice president of research and development of the Company Dr.Yossi Shaaltiel said the manufacturing and production capacity of the company exceeds its needs, and they would certainly be happy to have the company producing the ZMapp drug for use.

The company said it knows how to do it effectively, in large quantities, and in a relatively short period of time.

Dr Shaaltiel said the company is more proficient in the genetic engineering of tobacco plants from which the ZMapp medication is drawn than any other plant.

Reports maintained that the facilities in northern Israel were more advanced, and better equipped than the greenhouses in the US where production of the ZMapp drug takes place.

Of the seven people infected with the Ebola virus known to have been treated with ZMapp, two have died a Liberian doctor and a Spanish priest.

The priest received only one of three planned doses.

Two Americans recovered, as well as two Africans who received ZMapp in Liberia.

Source: Times of Israel